Successful Management of Acute Promyelocytic Leukemia in a Patient Who Presented With Acute Ischemic Stroke on Top of Subdural Hematoma

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 9; p. e45243
• Main Authors: Mallah, Shatha, Owda, Fahed, Hamayel, Hamza, Enaya, Ahmad, Mallah, Osama, Abugaber, Dina, Odeh, Razan
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 14.09.2023; Cureus
• Subjects: Anesthesia; Biopsy; Blood platelets; Blood pressure; Bone marrow; Case reports; Chemotherapy; Consciousness; Hematology; Hematoma; Hemoglobin; Hemorrhage; Internal Medicine; Ischemia; Leukemia; Magnetic resonance imaging; Medical imaging; Mortality; Oncology; Remission (Medicine); Stroke; Thrombosis; Ventilators; all-trans retinoic acid (atra); aml; subdural hematoma; acute promyelocytic leukemia; aml-m3; case report; disseminated intravascular coagulation (dic); apl; ischemic stroke
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.45243

Acute promyelocytic leukemia (APL), a distinct subtype of acute myelogenous leukemia (AML), is commonly associated with a heightened risk of bleeding due to coagulopathy. Thrombotic events, although less frequent, have also been linked to APL. However, the occurrence of ischemic stroke as an initial presentation of APL, particularly concomitant with central nervous system (CNS) bleeding, is exceedingly rare. The combination of these two complications is not reported in APL patients and is anticipated to carry a high mortality rate even with treatment. In this report, we describe the case of a young female patient with no significant medical history, who presented with decreased consciousness and recurrent seizures. Brain magnetic resonance imaging (MRI) revealed the simultaneous occurrence of acute ischemic stroke and acute-on-chronic subdural hematoma. The subsequent bone marrow biopsy confirmed the diagnosis of APL, displaying the characteristic positive promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARA) t(15;17) translocation. The patient was promptly initiated on a high-risk AML-M3 protocol, coupled with supportive treatment through platelet transfusion. Remarkably, a favorable response to treatment was observed, and a marked improvement in her neurological parameters was observed within 2 weeks duration of treatment. Subsequent assessment through a bone marrow biopsy one month later revealed complete remission, with the PML-RARA fusion gene becoming negative following a single course of consolidation therapy.